Ocugen Inc. closed 73.92% short of its 52-week high of $2.11, which the company reached on March 25th.

Ocugen has received approval from the DSMB to begin dosing the second cohort of patients in a trial of OCU200 for diabetic ...

Ocugen Inc. closed 75.47% below its 52-week high of $2.11, which the company reached on March 25th.

Ocugen (OCGN) announced that the Data and Safety Monitoring Board for the OCU200 clinical trial recently convened and reviewed safety data ...

MALVERN, Pa. - Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company specializing in gene therapies for eye diseases, has received approval from the Data and Safety Monitoring Board (DSMB ...

MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced progress in its Phase 1 clinical trial for OCU200, a novel biologic ...

Full Year 2024 Results Key Financial Results Net loss: US$54.1m (loss narrowed by 14% from ...

Ocugen (OCGN) stock was up today after the biotech company posted results from its Q4 2024 earnings report. Earnings per share reported during ...

Operator Good morning, and welcome to Ocugen's fourth quarter and full-year 2024 financial results and business update.

Tiffany Hamilton; Head of Communications; Ocugen Inc. Shankar Musunuri; Chairman of the Board, Chief Executive Officer & Co-founder; Ocugen Inc. Ramesh Ramachandran; ...

Ocugen has scheduled a conference call and webcast for 8:30 a.m. ET today to discuss the financial results and recent ...

Throughout the last three months, 5 analysts have evaluated Ocugen OCGN, offering a diverse set of opinions from bullish to bearish. The table below offers a condensed view of their recent ratings ...